38 results about "Invasion metastasis" patented technology

The invention relates to application of periplocin in anti-lung adenocarcinoma drugs and a target screening method of periplocin. Periplocin can be used for preparing anti-cancer drugs for treating lung adenocarcinoma, and can inhibit proliferation, invasion and metastasis of lung adenocarcinoma cells and induce apoptosis of the lung adenocarcinoma cells. Meanwhile, the invention also provides a method for screening anti-lung adenocarcinoma related targets of periplocin by combining transcriptomics with network pharmacology, which comprises the following steps: firstly, searching effective active components and prediction action targets of periplocin through a TCMSP database, constructing network pharmacology to screen key components and targets, and then constructing and analyzing a regulatory network. Intersection genes are determined in combination with transcriptomics, and a new thought is provided for lung adenocarcinoma treatment and drug research and development.

The application belongs to the technical field of biotechnology and gene therapy, and particularly relates to application of SNIP1 protein as a target in preparation or screening of an antitumor drug. The application finds that the SNIP1 protein is a non-histone substrate of lysine methyltransferase KMT5A, which promotes breast cancer cell growth, invasion and lung metastasis through KMT5A-mediated K301 monomethylation; therefore, the SNIP1 protein can be used as a target for screening of an antitumor drug, and a drug obtained by screening and inhibiting methylation of the K301 site of the SNIP1 protein can be used for antitumor; and the application provides a polypeptide specifically combined with the K301 site of the SNIP1 protein, the polypeptide is combined with the K301 site of the SNIP1 protein, inhibits methylation of the SNIP1 protein, and finally can inhibit tumor growth, proliferation, invasion and metastasis, and can be used as a new targeted antitumor drug.

The invention discloses an application of a phellinus igniarius extract in preparation of a lung cancer H1299 cell inhibitor, the active ingredient of the inhibitor comprises the phellinus igniarius extract, and the inhibitor at least has the following functions: a, inhibiting proliferation and clone formation of lung cancer H1299 cells; b, inhibiting the invasion and metastasis capability of lung cancer H1299 cells; c, arresting the cell cycle of the lung cancer H1299 in the S period; and d, the lung cancer H1299 cyclin Cyclind1 is down-regulated, the pro-apoptotic protein Bax is up-regulated, and the expression of p-AKT and Bcl-2 proteins is inhibited. The phellinus igniarius extract is phellinus igniarius extract powder or phellinus igniarius extract liquid, and the concentration of the phellinus igniarius extract liquid is 0.1-1.0 mg / ml. According to the application of the phellinus igniarius extract in preparation of the lung cancer H1299 cell inhibitor, a new thought is provided for preparation and / or screening of lung cancer drugs, a good working foundation is laid, and a new strategy is provided for clinical application.

The invention discloses a tsRNA marker related to colorectal cancer and application of the tsRNA marker. The nucleotide sequence of the tsRNA marker is as shown in SEQ ID NO: 1. By knocking down the tsRNA provided by the scheme of the invention, proliferation, invasion and metastasis of colorectal cancer cells can be inhibited, apoptosis can be promoted, and a new and powerful molecular biological tool is provided for treatment of colorectal cancer. The method has profound clinical significance and important popularization and application prospects.

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

The invention relates to an application of a synthetic peptide targeting CLDN12 in reduction of hepatic metastasis of pancreatic cancer. Research finds that the tight junction protein Claudin12 (CLDN12) is expressed on the surface of pancreatic cancer cells and also expressed on fibroblasts, and the CLDN12 on the fibroblasts and the CLDN12 on the pancreatic cancer cells mediate an adhesion effect through homologous interaction and guide migration and invasion of the pancreatic cancer cells. The adhesion effect of CLDN12-mediated fibroblasts and pancreatic cancer cells is blocked, and the invasion of the pancreatic cancer cells dominated by the fibroblasts can be blocked, so that the invasion and metastasis of the pancreatic cancer are reduced.

The invention discloses an application of an LAMP1 inhibitor in preparation of a medicine for preventing and / or treating esophageal cancer. Specifically, the application value of the LAMP1 inhibitor Parishin C in esophageal cancer treatment is found and verified for the first time, invasion and metastasis of esophageal squamous carcinoma cells and in-vivo lymph node metastasis can be remarkably inhibited by targeting LAMP1 protein and downstream signal channels of the LAMP1 protein and Parishin C, and a new drug choice is provided for metastatic esophageal cancer lacking effective treatment means clinically.

The invention discloses a euphorbia helioscopia seed extract as well as a preparation method and application thereof in preparation of an anti-lung cancer medicine, and belongs to the field of biological medicines. The preparation method comprises the following steps: performing vortex extraction, centrifugation and concentration on a methanol extracting solution to prepare a euphorbia helioscopia seed extract; wide targeted metabonomics research results show that chemical components of the euphorbia helioscopia seed extract and chemical components of the euphorbia helioscopia whole herb extract are remarkably different. Experimental results show that the euphorbia helioscopia seed extract provided by the invention has strong toxicity to lung cancer A549 cells, has a remarkable inhibition effect on EMT generation and invasion and metastasis capacities in the A549 cells induced by TGF-beta1, and can be used for preparing medicines for resisting lung cancer. The invention provides technical support for development of the euphorbia helioscopia seed extract as a novel anti-lung cancer drug, lays a foundation for full utilization of euphorbia helioscopia seed resources, and has a wide application prospect.

The present invention belongs to the field of biomedicine technology, and discloses the use of a quercetin derivative Q3MG in the preparation of anti-tumor invasion and metastasis drugs and drugs for targeted degradation of pro-IL-1β protein in cancer cells. The present invention first discovered that Q3MG can significantly inhibit tumor invasion and metastasis by targeted degradation of pro-IL-1β protein in cancer cells, and has a good therapeutic effect on anti-tumor invasion and metastasis, especially squamous cell carcinoma; it reveals the importance of quercetin derivatives in the preparation of drugs for the treatment of squamous cell carcinoma invasion and metastasis, and even the potential value of flavonoid compounds in various other tumors, which has far-reaching clinical significance and important prospects for promotion and application.

The invention discloses a drug curative effect prediction model for probiotic combined treatment of colon cancer, a construction method and a device, and belongs to the technical field of biological medicines. The invention provides a method for treating colon cancer through combination of probiotics, a mathematical model is constructed at the same time, the influence of an alpha value on the speed of a system tending to be balanced is analyzed, and it is obtained that initial conditions only influence the speed of the system tending to be balanced and do not influence the stability of the system. Meanwhile, the analysis of the influence of the drug dosage on the immune system finds that the tumor removal time can be obviously shortened by the full-dose triple therapy, the curative effect is obviously improved compared with that of a single drug or double drugs, and the action mechanism of a combined therapy scheme is disclosed: the invasion and transfer rate of CD4 + T cells can be obviously improved by increasing probiotics while the chemical immunotherapy dosage is fixed; the anti-tumor mechanism of the probiotics is to accurately adjust the immune system.

The invention belongs to the technical field of biological medicines, and relates to an A.muciniphila bacterium and an application of an outer membrane vesicle of the A.muciniphila bacterium in relieving chronic stress-mediated colorectal cancer progress. The product provided by the invention can effectively improve the influence of chronic stress on the tumor growth of colorectal cancer mice, and specifically comprises the following steps: inhibiting and / or relieving weight loss, relieving intestinal function damage, relieving tumor load increase, reducing tumor cell proliferation activity, and relieving or inhibiting the growth, invasion and metastasis of tumors. The invention provides a new treatment strategy for colorectal cancer patients accompanied by chronic stress.

The invention discloses application of Keratin5 low expression and PADI3 nuclear translocation in serving as a predictive marker for invasion and metastasis of head and neck squamous cell carcinoma, belongs to the technical field of biological medicine, verifies clinical applicability of KRT5 low expression and / PADI3 nuclear translocation (namely KRT5low / PADI3nucle) serving as a predictive index so as to fill the blank of the prior art, and provides a novel predictive marker for invasion and metastasis of head and neck squamous cell carcinoma. A novel molecular marker and an intervention target spot are provided for precise diagnosis and treatment of the head and neck squamous cell carcinoma; the KRT5 and PADI3 co-expression region forms a specific micro-domain difference and a specific mode in tumor tissues, can be used as an effective head and neck squamous cell carcinoma metastasis prediction marker, and has important scientific significance and application value for optimizing clinical diagnosis and treatment strategies.

The invention discloses a piRNA marker related to colorectal cancer and application of the piRNA marker. The nucleotide sequence of the piRNA is shown as SEQ ID NO: 1. The piRNA molecule provided by the invention can be used as a marker for diagnosing the colorectal cancer, and the colorectal cancer can be accurately detected by detecting the piRNA molecule; meanwhile, by inhibiting expression of piRNA molecules, proliferation, invasion and metastasis of colorectal cancer cells can be effectively inhibited, and a novel powerful molecular biological tool is provided for treatment of colorectal cancer. The method has profound clinical significance and important popularization and application prospects.

The invention discloses a construction method of an in-vitro liver cancer liver invasion and metastasis experimental model, and relates to the technical field of model construction, and the construction method comprises the following steps: culturing liver cancer cells and hepatic stellate cells, carrying out fluorescence labeling, generating a space coordinate set by using the fluorescence labeled liver cancer cells and hepatic stellate cells, and calculating the in-vitro liver cancer liver invasion and metastasis experimental model. The method comprises the following steps of: printing liver cancer cells and hepatic stellate cells according to a space coordinate set to generate a three-dimensional cell-matrix structure, pouring photoresponse hydrogel into the three-dimensional cell-matrix structure, and inducing HOTAIR long non-coding RNA concentration by using a transforming growth factor to obtain the three-dimensional cell-matrix structure integrated with the photoresponse hydrogel. The space coordinate set is generated through the Markov model, accurate simulation of radial distribution of the highly invasive liver cancer cell core area and the hepatic stellate cells is achieved, and an accurate position template is provided for printing of a three-dimensional cell-matrix structure.

The invention relates to the field of biological medicine, and discloses application of GABRR1 as a tumor marker and a target molecule. According to the application disclosed by the invention, the GABRR1 is discovered as a marker of tumor invasion and metastasis for the first time and participates in growth and invasion and metastasis processes of tumors, so that the GABRR1 can be used as a target spot in diagnosis and / or treatment of the tumors; according to the invention, the GABRR1 protein is used as a tumor target for screening to obtain a monoclonal antibody, a polypeptide or a small molecule drug and other tumor treatment drugs capable of overexpressing GABRR1.

The invention discloses application of combination of LIMK1 and CDK5 inhibitors in preparation of drugs for treating and / or preventing esophageal cancer, and belongs to the technical field of biological medicines. It is found for the first time that the combination of the LIMK1 inhibitor and the CDK5 inhibitor can inhibit invasion and metastasis of esophageal cancer. The LIMK1 inhibitor and the CDK5 inhibitor provided by the invention, as a medicine for treating and / or preventing esophageal cancer, have a remarkable synergistic effect and good safety.

The application relates to an ovary organ chip, a manufacturing method and application thereof. The ovary organ chip is sealed by a four-layer structure from top to bottom, and comprises an upper ovary chip layer, a follicle culture layer, a porous filter membrane layer and a lower ovary chip layer. An upper end of an upper culture medium perfusion chamber of the upper ovary chip layer is communicated with an upper inlet pool through an upper perfusion channel, and a lower end of the upper culture medium perfusion chamber is communicated with an upper outlet pool through the upper perfusion channel. An upper end of a lower culture medium perfusion chamber of the lower ovary chip layer is communicated with a lower inlet pool through a lower perfusion channel, and a lower end of the lower culture medium perfusion chamber is communicated with a lower outlet pool through the lower perfusion channel. The follicle culture layer is provided with a round hole or a cylinder. The ovary organ chip is constructed to simulate the physiological environment and pathological changes of substantial cells in an ovary in vitro, so that researches on hormone synthesis, ovary development and maturation, disease occurrence mechanism, tumor occurrence, development, invasion and metastasis and the like are carried out, and the ovary organ chip is used for researching and developing drugs, individualized treatment of tumors and fertility preservation.

The present invention relates to the field of biomedicine and discloses the application of GABRR1 as a tumor marker and a target molecule. The present invention firstly discovers that GABRR1 serves as a marker for tumor invasion and metastasis and participates in the processes of tumor growth, invasion and metastasis. Therefore, GABRR1 can be used as a target in the diagnosis and / or treatment of tumors; the present invention uses the GABRR1 protein as a tumor target to screen tumor therapeutic drugs such as monoclonal antibodies, polypeptides or small molecule drugs that can overexpress GABRR1.

The invention belongs to the technical field of biological medicine, and relates to application of PARVA as a target spot in lung cancer prevention and treatment. Specifically, the invention provides application of PARVA in preparation of drugs for treating or preventing lung cancer and application of PARVA in reagents or kits for diagnosis or prognosis evaluation of lung cancer. The invention further provides a lung cancer treatment medicine or a lung cancer prevention medicine taking PARVA as a target spot and a kit which comprises a reagent for detecting PARVA mRNA or protein expression and is used for lung cancer diagnosis or lung cancer prognosis evaluation. The invention provides application of PARVA as a target spot in prevention and treatment of lung cancer, and lung cancer cell proliferation, invasion and metastasis and tumor angiogenesis are inhibited by regulating and controlling expression or functions of PARVA in lung cancer cells and tumor microenvironment, so that effective treatment, early diagnosis, recurrence prevention and prognosis evaluation of lung cancer are realized.

The invention relates to the technical field of biology, discloses application of FMNL1 malonylation modification in inhibition of ccRCC transfer, and inhibits ccRCC transfer and invasion by promoting the FMNL1 malonylation modification level. The malonylation modification site of the FMNL1 is located at the 852 site of the FH2 functional structure domain; the malonylation modification level of lysine at the 852 site of the FMNL1FH2 functional structural domain is promoted, and migration and invasion of ccRCC are inhibited. According to the application of the FMNL1 malonylation modification in inhibition of ccRCC metastasis, in-vivo and in-vitro tests verify that the FMNL1 malonylation modification level can inhibit ccRCC invasion and metastasis, so that FMNL1 malonylation is a key target spot for regulating ccRCC invasion and metastasis, and based on the target spot, drugs for inhibiting renal clear cancer cell metastasis can be researched and developed.

The invention discloses application of herba lycopi flavone in preparation of a medicine for treating HBV-HCC (Hepatitis B Virus-Hepatitis C Chromatography), and belongs to the technical field of biological medicines. In-vivo experiments prove that CP can effectively inhibit proliferation and metastasis of HBV-HCC (Hepatitis B Virus-Hepatitis C Chromatography) cells. In combination with in-vitro cell activity, it is proved that eupatorium flavone is the most bioactive component for inhibiting HBV-HCC cell growth, proliferation and metastasis in CP. By inhibiting the HIF-1alpha and the downstream effect of the HIF-1alpha on VEGFA signal transduction, angiogenesis induced by tumors is hindered, the growth of the tumors is limited, and the invasiveness of cancer cells is reduced, so that the possibility of metastasis is reduced. It is verified that the herba lycopi flavone can inhibit invasion and metastasis of HBV-HCC through an HBx / HIF-1alpha / VEGFA signal axis; growth and proliferation and cell metastasis of HBV-HCC cells are inhibited through an HIF-1alpha / VEGFA signal channel, so that a scientific basis is provided for anti-tumor of the herba lycopi flavone.

The present invention relates to the field of genetic engineering, specifically to a biomarker oxoglutarate dehydrogenase analog (Oxoglutarate Dehydrogenase L; OGDHL) for predicting liver cancer metastasis and prognosis. The present invention also provides the use of a reagent for detecting the expression amount of OGDHL in liver cancer cells in the preparation of a kit for predicting liver cancer invasion and metastasis, and the use of OGDHL in the preparation of a drug for inhibiting liver cancer invasion and metastasis. The present invention provides a biomarker OGDHL for predicting liver cancer metastasis and prognosis, and reveals that increasing the expression level of OGDHL in cancer cells will effectively inhibit the invasion and metastasis of liver cancer. The conclusion of the present invention explains why low expression of OGDHL is widely prevalent in liver cancer cells, and provides a theoretical basis for evaluating the value of OGDHL in clinical samples as a new target for liver cancer diagnosis, prognosis, and treatment.

The application discloses an oncogene VGLL1 and application of a protein coded by the oncogene VGLL1, and particularly discloses application of a VGLL1 gene and / or a coded protein thereof in preparation of a medicine for treating cancer, and application of the VGLL1 gene and / or the coded protein thereof in preparation of a reagent or a kit for cancer diagnosis and / or prognosis judgment. It is found in the application that the oncogene VGLL1 has an important role in the occurrence and development process of tumors, and high expression of VGLL1 can induce malignant progression such as invasion and metastasis of ovarian cancer. It is also found in the research result that conditionally down-regulating VGLL1 can effectively relieve the growth of ovarian cancer cells and inhibit the invasion and metastasis ability of the ovarian cancer cells. The application provides a new diagnosis and treatment idea and a drug screening platform for solving clinical problems such as metastasis of ovarian cancer.

The invention belongs to the technical field of protein engineering, and particularly relates to a functional site for inhibiting tumor cell migration of a targeted ACAP4 protein and application of the functional site. And the site is any one or a combination of more of Patch2, Pair 2, Pair 3 and Pair 4. The ACAP4BAR crystal is obtained through crystal screening, the structure of the ACAP4BAR crystal is analyzed, seven positive charge enrichment regions on the surface of ACAP4BAR-PH are analyzed and found, and four key sites influencing cell migration are found. The four sites provided by the invention have a certain regulation effect on cell membrane localization of ACAP4 protein, can regulate the cell migration ability, and provide a molecular basis and a theoretical basis for treatment of diseases, cancer invasion and metastasis and the like caused by related protein dysfunction.

The present invention belongs to the technical field of tumor molecular biology, and particularly relates to the application of circSTX6 in the preparation of diagnostic and / or prognostic and therapeutic agents for nasopharyngeal carcinoma, as well as diagnostic and therapeutic agents. It is first discovered that circSTX6 is differentially expressed in nasopharyngeal carcinoma, can be used as a diagnostic or prognostic molecular marker, and may also become a potential target for the treatment of nasopharyngeal carcinoma. In the present invention, antisense oligonucleotides (ASO) are used to design sequences against the splicing sites at the head-to-tail junction of circular RNAs to interfere with circSTX6, and Matrigel invasion experiments and scratch healing experiments are carried out in nasopharyngeal carcinoma cell lines HNE2, CNE2 and HONE1. Compared with the NC group, the invasion and migration abilities of cells in the ASO group are significantly weakened, that is, silencing circSTX6 inhibits the invasion and metastasis of nasopharyngeal carcinoma cells, that is, inhibiting circSTX6 can treat nasopharyngeal carcinoma, which has profound clinical significance and important prospects for popularization and application.

The invention provides an anti-tumor composition as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The anti-tumor composition disclosed by the invention is prepared from the following raw materials in parts by mass: 18 to 22 parts of ginsenoside Rg3, 3 to 7 parts of ginsenoside CK, 28 to 32 parts of ganoderma lucidum polysaccharide, 23 to 27 parts of astragalus polysaccharide, 8 to 12 parts of lentinan, 16 to 20 parts of panax notoginseng saponins, 9 to 11 parts of resveratrol, 13 to 17 parts of curcumin, 6 to 10 parts of dihydromyricetin and 7 to 9 parts of sophocarpidine. The ratio of the total mass of the ganoderan and the astragalus polysaccharide to the total mass of the ginsenoside Rg3 and the panax notoginseng saponins is (1.3-1.6): 1. Through a multi-target and multi-path synergistic effect mechanism, tumor cell proliferation can be directly inhibited, apoptosis can be induced, the cell cycle can be retarded, tumor angiogenesis can be inhibited, the immune function of the body can be enhanced, the antioxidant effect can be exerted, tumor invasion and metastasis can be inhibited, meanwhile, the obvious synergistic and toxicity reducing effects can be shown in combined chemotherapy application, and the application prospect is wide. And a new technical scheme is provided for comprehensive treatment of tumors.

The application discloses application of a substance for inhibiting expression of ZNF8 protein in preparation of a product for preventing and treating cancer. Experiments prove that the ZNF8 protein can be combined with p53 protein; the expression of the ZNF8 protein can increase transcriptional activity of the p53 protein, down-regulate expression of VEGF gene and ANGPLT4 gene, inhibit proliferation of tumor cells, inhibit migration of tumor cells, inhibit transfer of tumor cells, inhibit invasion and transfer of tumor cells, inhibit formation of blood vessels, inhibit growth of tumors, inhibit transfer of tumors, inhibit lung transfer of tumors and improve survival rate of tumor-bearing animals, so that the expression of the ZNF8 protein has important application value in inhibition of growth and invasion and transfer of tumors; the expression of the ZNF8 protein can prevent and treat cancer.

The present invention belongs to the field of biomedicine, and specifically relates to the application of T5224 in inhibiting the invasion and metastasis of liver cancer. Specifically, the present invention provides the application of T5224, a small molecule compound targeting MAP1S, in treating MAP1S-related diseases, specifically, the MAP1S-related diseases include liver cancer, liver cancer metastasis, diseases caused by hepatitis B virus, etc.

The present application provides the application, method and drug related to the regulation of tumor or inflammatory disease related macrophage infiltration by CREPT. The present application also provides the application of the inhibition of CREPT positive tumor associated macrophage (TAM) in the preparation of the preparation for regulating the tumor microenvironment, and the application in the preparation of the drug for treating tumor or promoting the action of T lymphocyte. The inhibition of the CREPT positive tumor associated macrophage (TAM) can provide a technical means for controlling tumor proliferation, invasion and metastasis. The CREPT positive tumor associated macrophage (TAM) can also be used as a biomarker for the risk of an individual suffering from tumor, or a biomarker for the development stage of the tumor of an individual, to judge the risk of an individual suffering from tumor or the stage and progress of the tumor of a tumor patient.

The invention discloses a CDKN2A and ISG15 interaction key site MET53 and an application of the CDKN2A and ISG15 interaction key site MET53. In particular to application of a CDKN2A protein MET53 site in preparation of products for diagnosing or inhibiting tumor immune escape, tumor epithelial-mesenchymal transition, tumor cell matrix metalloproteinase expression quantity and tumor cell PD-L1 level and a method for preparing cancer cells with inhibited invasion and metastasis capacity, and provides a new way for precise diagnosis and treatment of tumors. The important clinical application value is realized.